reuters.com · 17 jun

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

U.S. pharmaceutical company ​Moderna is interested ‌in investing in production facilities in ​Germany, with ​an eye on ⁠plants that its ​German rival ​BioNTech plans to close, CEO Stephane Bancel ​told the ​German business daily Handelsblatt ‌on ⁠Wednesday.

zacks.com · 4 jun

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

zacks.com · 1 jun

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

globenewswire.com · 30 may

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).

globenewswire.com · 22 may

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.

globenewswire.com · 15 may

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly.

marketbeat.com · 15 may

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network.

fool.com · 13 may

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.